A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Fox Chase Cancer Center
EpicentRx, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
National Cancer Center, Korea
Gilead Sciences
Leo W. Jenkins Cancer Center
Daiichi Sankyo
National Cancer Institute (NCI)
Western Regional Medical Center
New Mexico Cancer Research Alliance
Merrimack Pharmaceuticals
Northwestern University
University of Miami
Merrimack Pharmaceuticals
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
New Mexico Cancer Research Alliance
University of Alabama at Birmingham
National Cancer Institute (NCI)
Fox Chase Cancer Center
Yale University
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Northwestern University
Roswell Park Cancer Institute
Hellenic Oncology Research Group
Sanofi
National Cancer Center, Korea
Kentuckiana Cancer Institute
National Cancer Institute (NCI)